Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO -2.45%77 Debt-to-Equity is 0.80 as of Jun. 2026, which is 16% above its 10-year median of 0.69. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $17.92 (Fairly Valued). The stock has 9 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 80.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bausch & Lomb's Debt-to-Equity or its related term are showing as below:
BLCO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.69 Max: 0.8
Current: 0.8
During the past 8 years, the highest Debt-to-Equity Ratio of Bausch & Lomb was 0.80. The lowest was 0.00. And the median was 0.69.
BLCO's Debt-to-Equity is ranked worse than 80.57% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs BLCO: 0.80
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bausch & Lomb Debt-to-Equity Related Terms
Bausch & Lomb Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLCO vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a Debt-to-Equity of 0.80 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bausch & Lomb and its competitors. This is 16% above median its historical median of 0.69. According to the industry distribution chart, Bausch & Lomb ranks #568 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 80.6%.
Is Bausch & Lomb's Debt-to-Equity too high?
Bausch & Lomb's current Debt-to-Equity of 0.80 is 16% above median its 10-year median of 0.69. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Bausch & Lomb's value of 0.80 is 247.8% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #568 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #568 out of 705 companies for Debt-to-Equity. This places Bausch & Lomb in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Bausch & Lomb's value of 0.80 is 247.8% above this benchmark. While the company's 10-year median is 0.69 vs. the industry median of 0.23, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current Debt-to-Equity of 0.80 is 247.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current Debt-to-Equity is 0.80, which is 16% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $17.92, compared to a current price of $16.35 — trading 8.8% below its estimated fair value. The current Debt-to-Equity is 0.80, which is 16% above median its 10-year median of 0.69 and 247.8% above the Medical Devices & Instruments industry median of 0.23. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Debt-to-Equity is 0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.35 is trading 8.8% below its estimated GF Value™ of $17.92.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
Debt-to-Equity: 0.80 (16% above median its 10-year median of 0.69)
GF Value™: $17.92 vs. price of $16.35 (8.8% below fair value)
Industry Position: 247.8% above the Medical Devices & Instruments median (#568 of 705)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
